GlaxoSmithKline Revenue Growth: 7.04%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GSK Revenue Growth Rankings
| Overall | 47th percentile | 2305 of 4424 |
| Sector | 46th percentile | 249 of 464 in Healthcare |
| Industry | 55th percentile | 9 of 20 in Drug Manufacturers - Major |
GSK Revenue Growth Range, Past 5 Years
| Minimum | 2.97% | Dec 2003 |
| Maximum | 45.22% | Jun 1995 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these GSK related companies
GSK News
Interesting to see $GSK boasting about how it is repatriates its cash from European operations so fast these days. Probably a wise move.
about 5 days ago by bradloncar
about 5 days ago by bradloncar
GlaxoSmithKline plc's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 07, 3:30PM Seeking Alpha
Feb 07, 3:30PM Seeking Alpha
Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen
Feb 07, 11:33AM PR Newswire
Feb 07, 11:33AM PR Newswire
$GSK IR on Twitter. Smart example. "GSK to announce 2011 year-end results [today] at noon GMT. We'll be using the hashtag #GSKFY11"
about 5 days ago by BHSMITH
about 5 days ago by BHSMITH
Anacor Pharmaceuticals Down 14.4% After GlaxoSmithKline Pauses Ongoing Trials
Feb 06, 9:20AM Benzinga
Feb 06, 9:20AM Benzinga
Glaxo (GSK) Halts Enrollment in GSK '052 Phase 2b Following Recent Discovery (ANAC)
Feb 06, 8:31AM Street Insider
Feb 06, 8:31AM Street Insider
$ANAC reports partner GlaxoSmithKline $GSK has voluntarily paused enrollment of ongoing GSK '052 Phase 1, 2 Clinical Trials; ANAC halted
about 6 days ago by Street_Insider
about 6 days ago by Street_Insider
Drastic day for healthcare, esp. with pneumonia-deaths in clinical trials! http://stks.co/1qHP $THRX $BMY $GSK $INHX $IDIX
about 34 days ago by juliat333
about 34 days ago by juliat333
$GSK http://stks.co/1oDf $GSK looking intersting here, looking @ Feb 46 call or ITM 45's
about 37 days ago by _TheBlackSwan_
about 37 days ago by _TheBlackSwan_
RT @BloombergNews Drug approvals hit a seven-year high | http://stks.co/1n8c $GSK $JNJ
about 38 days ago by brittpierpoint
about 38 days ago by brittpierpoint
@Dostoevsky $HGSI has a few other drugs in development, in addition to a long-term relationship with $GSK
about 53 days ago by samlee22
about 53 days ago by samlee22
$GSK to sell 17 OTC brands in North America to $PBH for $660M; PBH shares up 7.8% pre-open
about 54 days ago by Street_Insider
about 54 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| HBAN | 5.91 | -0.12 | -2.07% | 5.10B |
| ABR | 4.54 | -0.05 | -1.09% | 115.50M |
| ANEN | 18.30 | -0.15 | -0.81% | 275.23M |
| RKT | 68.04 | 0.53 | 0.79% | 4.80B |
| IHG | 21.93 | 0.07 | 0.32% | 6.37B |
| MCO | 38.44 | 0.07 | 0.18% | 8.53B |
| FLR | 59.57 | -0.65 | -1.08% | 10.35B |
| BRCD | 5.80 | -0.14 | -2.36% | 2.85B |
| ENTR | 7.09 | -0.17 | -2.27% | 615.77M |